PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 78 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $438,000 | -78.9% | 62,166 | -64.0% | 0.01% | -76.0% |
| Q3 2019 | $2,074,000 | -20.6% | 172,706 | -20.0% | 0.05% | -10.7% |
| Q2 2019 | $2,613,000 | +46.5% | 215,756 | +52.0% | 0.06% | +43.6% |
| Q1 2019 | $1,784,000 | +88.4% | 141,945 | +0.9% | 0.04% | +56.0% |
| Q4 2018 | $947,000 | -50.3% | 140,714 | -25.0% | 0.02% | -37.5% |
| Q3 2018 | $1,904,000 | +70.5% | 187,653 | +14.7% | 0.04% | +90.5% |
| Q2 2018 | $1,117,000 | -21.5% | 163,667 | -1.2% | 0.02% | -30.0% |
| Q1 2018 | $1,423,000 | +109.3% | 165,606 | +397.3% | 0.03% | +100.0% |
| Q4 2017 | $680,000 | – | 33,302 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |